Q32 Bio
PublicQ32 Bio is now publicly traded
The data on this page reflects Q32 Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Mar 25, 2024
Total Funding Raised
$148M
Company Overview
Q32 Bio (NAS: QTTB) is a biotechnology company focused on developing innovative biologics to restore immune balance in patients with autoimmune and inflammatory diseases through antibody-based therapeutics.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Q32 Bio Comparables
Compare Q32 Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Attovia Therapeutics | 61% | |
| Linno Pharmaceuticals Inc. | 60% |
Q32 Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Mar 25, 2024 | ||||
| Series B | Oct 29, 2020 | ||||
| Series A | May 27, 2020 |
Q32 Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Private Placement |
| Osage University Partners | Series B, Private Placement |
| OrbiMed | Series A, Private Placement, Series B |
| Accomplice | Series B, Private Placement, Series A |
| Acorn Bioventures | Private Placement, Series B |
| Abingworth | Series A, Series B, Private Placement |
| Sanofi Ventures | Series A, Series B, Private Placement |
Q32 Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access